Autologous Anti-CD19 CAR-IL-18-expressing T-lymphocytes

Preferred Label : Autologous Anti-CD19 CAR-IL-18-expressing T-lymphocytes;

NCIt synonyms : Autologous Anti-CD19 CAR IL-18-expressing T Cells; huCART19-IL18;

NCIt definition : A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), and expressing the pro-inflammatory cytokine interleukin 18 (IL-18), with potential antineoplastic activity. Upon intravenous administration, autologous anti-CD19 CAR-IL-18-expressing T-lymphocytes target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-18 promotes T-cell persistence and potentiates the immune response against tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of costimulatory signaling domains increases human T-cell function, expansion, and survival.;

NCI Metathesaurus CUI : CL1662184;

Details

Origin ID

C179603;

UMLS CUI

C5555808;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients